Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance for 2024 TrinScreen HIV Sales

Barchart · 05/13 10:42

DUBLIN, Ireland, May 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to approximately $6 million.